Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.

doi:10.1007/s12185-023-03696-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.

International journal of hematology - 1 Nov 2024

Yokoyama Yasuhisa

Abstract excerpt

The treatment of acute promyelocytic leukemia (APL) has evolved with the introduction of all-trans retinoic acid (ATRA) and subsequent arsenic trioxide (ATO), particularly in standard-risk APL with an initial white blood cell count (WBC) < 10,000/μL, where a high cure rate can now be achieved. However, for some patients with risk factors, early death or relapse remains a concern. Insights from the analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Drug Resistance, Neoplasm
Share to fms-Like Tyrosine Kinase 3
Share to Leukemia, Promyelocytic, Acute
Share to Leukocyte Count
Share to Risk Factors
Share to Tretinoin
Share to Tumor Protein p73

Source

Open in PubMed

Identifiers

PMID: 38386203
DOI: 10.1007/s12185-023-03696-7

Provenance

PubMed metadata and Literature Corpus relationships.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics